Biote Stock (NASDAQ:BTMD), Trade Ideas

Biote

Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations.

Long Ideas

News

Penny Stocks

Small Cap

Insider Trades

Markets

Trading Ideas

BTMD

CRYM

ERAS

HOWL

The Dow Jones closed higher on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Over $4 Million Bet On Werewolf Therapeutics? Check Out These 4 Penny Stocks Insiders Are Buying

Pre-Market Outlook

Movers

AMPE

ATXG

AVCT

BIAF

CEMI

CLBS

GFAI

GSUN

Hollsys Automation Technologies INTERNATIONAL

HOLI

ISPO

KPTI

LULU

NBEV

NINE

PIXY

PXMD

SGML

SHIP

SHPH

TAOP

VRAX

RVPH

Why Pagerduty Is Trading Higher By 9%; Here Are 28 Stocks Moving Premarket

AIHS

BGXX

CFRX

CMRA

FIVE

GRNQ

HIVE

HPCO

MEGL

NTNX

NUWE

NVDA

OBSV

OKTA

PSTG

SMTC

SONN

STIX

THMO

TIVC

VEEV

VXRT

ZFOX

Gainers


	Bright Green Corporation (NASDAQ: BGXX) shares rose 63.8% to $2.26 in pre-market trading after gaining around 33% on Wednesday.


Why Nutanix Is Trading Higher By 16%; Here Are 33 Stocks Moving Premarket

Biote Corp

Guggenheim analyst Michael Schmidt reiterates Immunocore Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) with a Buy and maintains $92 price target.

Price Target

Reiteration

Analyst Ratings

IMCR

Guggenheim Reiterates Buy on Immunocore Hldgs, Maintains $92 Price Target

B. Riley Securities analyst Lucas Pipes maintains AZZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) with a Buy and raises the price target from $67 to $85.

B. Riley Securities Maintains Buy on AZZ, Raises Price Target to $85

Guggenheim analyst Vamil Divan reiterates ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) with a Buy and maintains $77 price target.

ANIP

Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $77 Price Target

<a href="https://twitter.com/mingchikuo/status/1782811499381342697">https://twitter.com/mingchikuo/status/1782811499381342697</a>
&nbsp;

AAPL

Apple Analyst Ming-Chi Kuo Posts On X "Apple Cuts 2024 & 2025 Vision Pro Shipment Forecasts, Unfavorable To MR Headset, Pancake, And Micro OLED Trends"

Truist Securities analyst Jordan Levy maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Buy and lowers the price target from $145 to $130.

ENPH

Truist Securities Maintains Buy on Enphase Energy, Lowers Price Target to $130

Truist Securities analyst Barry Jonas maintains Everi Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVRI#NYSE">EVRI</a>) with a Hold and lowers the price target from $13 to $11.

EVRI

Truist Securities Maintains Hold on Everi Hldgs, Lowers Price Target to $11

WIIM

Disney shares are trading higher after Wells Fargo maintained an Overweight rating and raised its price target from $128 to $141.

TD Cowen analyst Frank Lee maintains Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) with a Buy and lowers the price target from $261 to $252.

TD Cowen Maintains Buy on Travelers Companies, Lowers Price Target to $252

On Tuesday, General Motors (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gm#NYSE">GM</a>) did a lot better than expected during the first three months of 2024. The Detroit automaker also lifted its 2024 guidance fueled by strong&nbsp;truck sales in North America.
<h3>First Quarter Highlights</h3>
During the first three months of the year, GM reported revenue rose&nbsp;7.6% YoY to&nbsp;$43.01 billion, surpassing LSEG&rsquo;s estimate of $41.92 billion.&nbsp;Net income grew 26% to $2.95 billion with adjusted earnings amounting to $2.62 per share, also surpassing LSEG&rsquo;s estimate of $2.15. When excluding some dividend payouts, net income attributable to stockholders rose 24.4% to $2.98 billion, or $2.56 per share.
GM&rsquo;s operations in North America were the star of the Q1 show.
The division reported adjusted earnings rose 7.4% YoY to $3.84 billion. With increased retail sales and steady pricing of vehicles, the division achieved an adjusted profit margin of 10.6%.&nbsp;
North America&rsquo;s success succeeded to offset the loss from weak divisions.
On the other hand, GM&rsquo;s divison in China reported a loss of $106 million, along with $10 million in other international markets. While highly profitable trucks continue to enjoy strong sales.
EV plans remain on track.
The EV universe was shaken when Tesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) reported its first YoY global sales drop since the pandemic. Moreover, Tesla also warned a year of slower growth is ahead. GM is among the many automakers that scaled down its EV ambitions.
But, GM is still aiming for an output in the range between 200,000 and 300,000 EVs this year.&nbsp;Moreover, GM forecasted its North American EV business will become profitable in the second half of the year, which would be a major milestone.
On the back of strong results, GM&nbsp;lifted its full-year guidance.
GM previously guided for&nbsp;2024 adjusted EBIT in the range between $12 billion and $14 billion.&nbsp;It now raised its guidance on both ends for half a billion.&nbsp;It also raised its&nbsp;2024 EPS from a previous range between $8.50 and $9.50to a new range between $9.00 and $10.00 per share.&nbsp;GM also raised its&nbsp;automotive operating cash flow forecast that is now between $18.3 billion and $21.3 billion, while guiding for adjusted automotive free cash flow in the range between $8.5 billion and $10.5 billion.
GM&rsquo;s first quarter results reflect&nbsp;resilience and strength.&nbsp;
Despite&nbsp;the increased labor costs from new&nbsp;union contracts, higher interest rates its customers are facing when buying cars and its EV business not being profitable yet, GM made more than expected. But when it comes to EVs, tonight will be the night of valuable insights for the industry as Tesla is due to report earnings. Even the mighty Tesla is undoubtedly feeling the pinch from the EV slowdown, along with intensifying competition in China.
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

Tech

General

TSLA

General Motors' Financials Rise Despite Headwinds

Truist Securities analyst Barry Jonas maintains Intl Game Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) with a Hold and lowers the price target from $28 to $26.

Truist Securities Maintains Hold on Intl Game Tech, Lowers Price Target to $26

Truist Securities analyst Barry Jonas maintains Golden Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEN#NASDAQ">GDEN</a>) with a Buy and lowers the price target from $45 to $44.

GDEN

Truist Securities Maintains Buy on Golden Entertainment, Lowers Price Target to $44

Truist Securities analyst Barry Jonas maintains Ballys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALY#NYSE">BALY</a>) with a Buy and raises the price target from $14 to $16.

BALY

Truist Securities Maintains Buy on Ballys, Raises Price Target to $16

-&nbsp; &nbsp; &nbsp;Expansion increases enterprise penetration for Vuzix as industry leader in tools for improved warehousing solutions

VUZI

Vuzix Received Additional Orders For Vuzix M400 Smart Glasses From Global Retailer; Terms Not Disclosed

Truist Securities analyst Barry Jonas maintains Caesars Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) with a Buy and lowers the price target from $62 to $58.

Truist Securities Maintains Buy on Caesars Entertainment, Lowers Price Target to $58

International Business Machines Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ibm#NYSE">IBM</a>) is scheduled to report first-quarter 2024 results on Apr 24, after the closing bell. In the to-be-reported quarter, the company is likely to have recorded higher revenues from the Software segment backed by growing demand for its advanced AI-driven solutions and product innovation.
<h3>Factors At Play</h3>
The Software segment includes Hybrid Platform &amp; Solutions comprising software services, Red Hat, automation and data &amp; artificial intelligence&nbsp;businesses and Transaction Processing. 
During the first quarter, IBM introduced LinuxONE 4 Express, an advanced data center solution designed to provide cybersecurity, scalability and AI inferencing for hybrid cloud environments. The solution&#39;s cutting-edge features make it suitable for a multitude of use cases for startups and small and medium-sized enterprises. 
With built-in hardware-based security technology and confidential computing capabilities, the solution effectively shields sensitive data and digital assets. It enhances protection against both external threats and insider breaches by enabling scalable isolation for individual workloads, while consolidation of databases into a LinuxONE system significantly lowers costs and streamlines IT environments. The seamless integration enables data analysis to be conducted exactly where the data is located. These are likely to have supported the top line in the Software segment. 
In the first quarter, IBM integrated the open-source Mixtral-8x7B large language model into its watsonx AI and data platform. The optimized version of Mixtral-8x7B, developed by Mistral AI, showcases impressive performance gains. Internal tests reveal a remarkable 50% increase in throughput compared to the standard model. By leveraging quantization techniques to reduce the model size and memory requirements, IBM anticipates significant reductions in latency, potentially ranging from 35% to 75%, depending on batch size. 
Mixtral-8x7B&#39;s incorporation underscores IBM&#39;s dedication to cutting-edge AI research and development. Built on innovative Sparse modeling and the Mixture-of-Experts technique, this model excels in rapid data processing and contextual analysis. Its ability to efficiently handle vast datasets makes it a valuable asset for businesses seeking actionable insights. All these are likely to be reflected in the upcoming results.
<h3>Overall Expectations</h3>
The Zacks Consensus Estimate for Software revenues is pegged at $5,998 million, indicating marginal growth from $5,921 million in the year-ago quarter. However, our estimate for revenues from Software is pegged at $6,140 million, suggesting a 3.7% improvement year over year. 
The Zacks Consensus Estimate for total revenues for the company stands at $14,577 million. It generated revenues of $14,252 million in the prior-year quarter. The consensus mark for earnings is currently pegged at $1.60 per share, indicating growth from $1.36 in the year-earlier quarter.
<h3>Earnings Whispers</h3>
Our proven model predicts an earnings beat for IBM for the first quarter. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is perfectly the case here. 
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is +0.39%.
<div class="chart_embed">
<h3>International Business Machines Corporation Price And EPS Surprise</h3>
<a href="https://www.zacks.com/stock/chart/IBM/price-eps-surprise?icid=chart-IBM-price-eps-surprise"><img alt="International Business Machines Corporation Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/10/1713869997.png" style="height:263px; width:545px" title="" /> </a>
International Business Machines Corporation price-eps-surprise | International Business Machines Corporation Quote
</div>
Zacks Rank: IBM has a Zacks Rank #3.
<h3>Other Stocks to Consider</h3>
Here are some other companies you may want to consider, as our model shows that these, too, have the right combination of elements to post an earnings beat this season: 
Qualcomm Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qcom#NASDAQ">QCOM</a>) is set to release quarterly numbers on May 1. It has an Earnings ESP of +2.78% and a Zacks Rank #3. 
The Earnings ESP for Silicon Motion Technology Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/simo#NASDAQ">SIMO</a>) is +5.96% and it carries a Zacks Rank of 2. The company is scheduled to report quarterly numbers on May 2. 
The Earnings ESP for Meta Platforms, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meta#NASDAQ">META</a>) is +0.62% and it carries a Zacks Rank of 2. The company is scheduled to report quarterly numbers on Apr 24.
<a href="https://www.zacks.com/stock/news/2259829/will-higher-software-revenues-benefit-ibm-s-q1-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2259829">To read this article on Zacks.com click here.</a>

Earnings

QCOM

SIMO

Will Higher Software Revenues Benefit IBM's Q1 Earnings?

Axcelis Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NYSE">ACLS</a>) short percent of float has risen 18.62% since its last report. The company recently reported that it has 1.97 million shares sold short, which is 8.92% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.9 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Axcelis Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713890723_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Axcelis Technologies has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Axcelis Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Axcelis Technologies's peer group average for short interest as a percentage of float is 6.81%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

ACLS

How Is The Market Feeling About Axcelis Technologies?

Prologis's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>) short percent of float has risen 21.19% since its last report. The company recently reported that it has 10.13 million shares sold short, which is 1.43% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.49 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Prologis Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713890717_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Prologis has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Prologis's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Prologis's peer group average for short interest as a percentage of float is 4.21%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(PLD) - Analyzing Prologis's Short Interest

Medical Properties Trust's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>) short percent of float has risen 5.01% since its last report. The company recently reported that it has 206.64 million shares sold short, which is 48.02% of all regular shares that are available for trading. Based on its trading volume, it would take traders 12.45 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Medical Properties Trust Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713890712_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Medical Properties Trust has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Medical Properties Trust's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Medical Properties Trust's peer group average for short interest as a percentage of float is 3.51%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Medical Properties Trust's Recent Short Interest

Truist Securities analyst Barry Jonas maintains Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) with a Hold and raises the price target from $58 to $60.

Truist Securities Maintains Hold on Red Rock Resorts, Raises Price Target to $60

Tuesday,&nbsp;Quest Diagnostics Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>)&nbsp;posted first-quarter adjusted EPS of $2.04, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.86</a>.
Sales came in at $2.37 billion, up 1.5% Y/Y, higher than the Wall Street&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/n38374605/quest-diagnostics-reports-first-quarter-2024-financial-results-raises-guidance-for-full-year-2024" rel="noreferrer noopener">estimate of $2.29 billion</a>.
&#8220;In the first quarter, we delivered nearly 6% base business revenue growth, continuing the strong momentum of recent quarters. We also grew total revenues for the first time since the height of the pandemic nearly three years ago,&#8221; said&nbsp;Jim Davis, Chairman, CEO&nbsp;and&nbsp;President.
&#8220;Our strong commercial focus on physicians and hospitals combined with our broad health plan access enabled us to take advantage of sustained high&nbsp;rates of healthcare utilization&nbsp;and drive new customer growth.&nbsp;Our investments&nbsp;within&nbsp;advanced diagnostics also&nbsp;enabled&nbsp;double digit&nbsp;growth within multiple key clinical areas, including brain health, women&#8217;s health&nbsp;and&nbsp;advanced cardiometabolic health,&#8221; Davis added.
Adjusted operating income slipped slightly from $350 million to $349 million.
Outlook:&nbsp;Quest Diagnostics expects fiscal year 2024 revenues of&nbsp;$9.4 billion-$9.48 billion&nbsp;versus the prior&nbsp;guidance&nbsp;of&nbsp;$9.35 billion-$9.45 billion&nbsp;and consensus of&nbsp;$9.40 billion.
The company forecasts 2024 adjusted EPS of&nbsp;$8.72-$8.97&nbsp;versus the prior&nbsp;guidance&nbsp;of&nbsp;$8.60-$8.90&nbsp;and consensus of&nbsp;$8.75.
William Blair&nbsp;notes that the stock&nbsp;is likely to&nbsp;rise today due to better-than-expected metrics and increased operating margins compared to the previous quarter.&nbsp;
This&nbsp;aligns with the focus of investor attention during the call, and the slight beat on this front&nbsp;is seen&nbsp;positively.&nbsp;
William Blair writes that Quest&nbsp;is poised&nbsp;for steady growth over the long term, supported by its strategies targeting trends in lab testing such as market consolidation, value-based contracts, advanced cancer diagnostics, and automation.&nbsp;
William Blair rates the&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/DGX/analyst-ratings" rel="noreferrer noopener">stock as Outperform</a>.
Price Action: DGX shares are up 4.32% at $135.72 at the last check Tuesday.
Photo via Shutterstock

Analyst Color

Equities

Large Cap

Guidance

Health Care

Quest Diagnostics Says Sales In Q1 Increased For The First Time Since The Height Of Pandemic

In a report released today, Les Sulewski from Truist Financial assigned a Buy rating to biote (BTMD – Research Report), with a price target of $5.5...

Truist Financial Issues a Buy Rating on biote (BTMD)

BIOTE&nbsp; GAAP EPS of $0.18 beats by $0.11, revenue of $45.7M in-line

biote Corp. (BTMD) Q4 2023 Earnings Call Transcript

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on biote (BTMD – Research Report), Incyte (INCY – Resea...

Analysts Are Bullish on Top Healthcare Stocks: biote (BTMD), Incyte (INCY)

Solid Biosciences, Cue Biopharma, Annexon among healthcare movers

biote (BTMD) has shared an announcement. Biote Corp. has recently shared its March 2024 Investor Presentation on its website, signaling an update f...

Biote Corp. Releases March 2024 Investor Presentation

biote (BTMD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jonna Kim from TD Cowen ma...

Optimistic Outlook: Biote's Growth Potential and Strategic Initiatives Despite Transitional Challenges

ADCT

ANNX

HRTX

INCY

PHVS

PIII

REVB

SLDB

Press Releases

Biote Reports Second Quarter 2023 Financial Results

Biote Schedules Third Quarter 2023 Financial Results Release and Conference Call

Biote Reports Third Quarter 2023 Financial Results

Biote Names Robert Peterson as Chief Financial Officer

Biote to Purchase Asteria Health

Biote Provides Preliminary 2023 Results and Initial 2024 Guidance

Biote Announces $20 Million Share Repurchase Authorization

Biote Announces Agreement to Resolve Litigation and Repurchase All of Founder's Shares

Biote Schedules Fourth Quarter and Full Year 2023 Financial Results Release and Conference Call